Integrated proximal proteomics reveals IRS2 as a determinant of cell survival in ALK-driven neuroblastoma
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
An adaptor protein in the insulin signaling pathway enables the survival of aggressive neuroblastoma cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global quantification of mammalian gene expression control
Schwanhäusser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., & Selbach, M. (2011) · Nature · doi:10.1038/nature10098 · Cited by 6,566
Critical nodes in signalling pathways: insights into insulin action
Taniguchi, C. M., Emanuelli, B., & Kahn, C. R. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1837 · Cited by 2,760
Identification of ALK as a major familial neuroblastoma predisposition gene
Mossé, Y. P., Laudenslager, M., Longo, L., Cole, K. A., Wood, A., Attiyeh, E. F., Laquaglia, M. J., Sennett, R., Lynch, J. E., Perri, P., et al. (2008) · Nature · doi:10.1038/nature07261 · Cited by 1,407 · cited 1×
“ALK is the major predisposition gene for familial NB (12, 13), and oncogenic ALK signaling drives a substantial subset of sporadic NBs.”
BackgroundSelf-citationDrugging the ‘undruggable’ cancer targets
Dang, C. V., Reddy, E. P., Shokat, K. M., & Soucek, L. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.36 · Cited by 927
Activating mutations in ALK provide a therapeutic target in neuroblastoma
George, R. E., Sanda, T., Hanna, M., Fröhling, S., II, W. L., Zhang, J., Ahn, Y., Zhou, W., London, W. B., McGrady, P., et al. (2008) · Nature · doi:10.1038/nature07397 · Cited by 893
The target landscape of clinical kinase drugs
Klaeger, S., Heinzlmeir, S., Wilhelm, M., Polzer, H., Vick, B., Koenig, P.-A., Reinecke, M., Ruprecht, B., Petzoldt, S., Meng, C., et al. (2017) · Science · doi:10.1126/science.aan4368 · Cited by 854 · cited 1×
“(40) for LDK378 and crizotinib including those reported by the suppliers (fig.”
BackgroundInsulin Receptor Substrate-2 Deficiency Impairs Brain Growth and Promotes Tau Phosphorylation
Schubert, M., Brazil, D. P., Burks, D. J., Kushner, J. A., Ye, J., Flint, C. L., Farhang-Fallah, J., Dikkes, P., Warot, X. M., Rio, C., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-18-07084.2003 · Cited by 488
Eberl, H. C., Spruijt, C. G., Kelstrup, C. D., Vermeulen, M., & Mann, M. (2013) · Molecular Cell · doi:10.1016/j.molcel.2012.10.026 · Cited by 189
Wang, H. Q., Halilovic, E., Li, X., Liang, J., Cao, Y., Rakiec, D. P., Ruddy, D. A., Jeay, S., Wuerthner, J. U., Timple, N., et al. (2017) · eLife · doi:10.7554/elife.17137 · Cited by 45 · cited 1×
“Although all cell lines are reported to have wild-type p53, additional factors may influence and modulate the functional survival response in the NB1 cells (68, 69).”
Background
Research works printed but not linked: 77
- 10.1038/nrdp.2016.78 · DOI · Paper page
- 10.1038/ng.2529 · DOI · Paper page
- 10.1126/science.6719137 · DOI · Paper page
- 10.1056/NEJM198510313131802 · DOI · Paper page
- 10.1093/emboj/16.11.2985 · DOI · Paper page
- 10.1016/j.ccr.2012.02.010 · DOI · Paper page
- 10.1126/scitranslmed.3003967 · DOI · Paper page
- 10.1016/j.ccr.2012.06.001 · DOI · Paper page
- 10.7554/eLife.09811 · DOI
- 10.1073/pnas.1520099112 · DOI · Paper page
- 10.1038/nature07398 · DOI · Paper page
- 10.1042/BJ20081834 · DOI · Paper page
- 10.1038/nature07399 · DOI · Paper page
- 10.1038/onc.2011.647 · DOI
- 10.1126/scisignal.2005470 · DOI
- J. Guan, E. R. Tucker, H. Wan, D. Chand, L. S. Danielson, K. Ruuth, A. El Wakil, B. Witek, Y. Jamin, G. Umapathy, S. P. Robinson, T. W. Johnson, T. Smeal, T. Martinsson, L. Chesler, R. H. Palmer, B. Hallberg, The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN. Dis. Model. Mech. 9, 941–952 (2016). · DOI
- 10.1158/2159-8290.CD-15-1056 · DOI · Paper page
- T. H. Marsilje, W. Pei, B. Chen, W. Lu, T. Uno, Y. Jin, T. Jiang, S. Kim, N. Li, M. Warmuth, Y. Sarkisova, F. Sun, A. Steffy, A. C. Pferdekamper, A. G. Li, S. B. Joseph, Y. Kim, B. Liu, T. Tuntland, X. Cui, N. S. Gray, R. Steensma, Y. Wan, J. Jiang, G. Chopiuk, J. Li, W. P. Gordon, W. Richmond, K. Johnson, J. Chang, T. Groessl, Y.-Q. He, A. Phimister, A. Aycinena, C. C. Lee, B. Bursulaya, D. S. Karanewsky, H. M. Seidel, J. L. Harris, P.-Y. Michellys, Synthesis, structure–activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J. Med. Chem. 56, 5675–5690 (2013). · DOI · Paper page
- 10.1016/j.ctrv.2017.03.006 · DOI
- 10.1016/S1470-2045(13)70095-0 · DOI · Paper page
- 10.1056/NEJMoa1007478 · DOI · Paper page
- 10.1016/j.ccell.2015.02.005 · DOI · Paper page
- 10.1016/j.cell.2006.09.026 · DOI · Paper page
- 10.2337/db06-0148 · DOI · Paper page
- 10.1038/nsmb.3218 · DOI · Paper page
- 10.1126/scisignal.2005769 · DOI · Paper page
- 10.1126/scisignal.aaf5011 · DOI
- 10.18632/oncotarget.12513 · DOI
- 10.1021/pr400417g · DOI
- 10.1038/bjc.1987.80 · doi:10.1038/bjc.1987.80
- 10.1016/j.febslet.2007.01.039 · doi:10.1016/j.febslet.2007.01.039
- 10.1074/mcp.M200025-MCP200 · DOI · Paper page
- 10.1038/sj.onc.1205735 · DOI
- 10.1074/mcp.M800407-MCP200 · DOI · Paper page
- 10.1038/nbt0307-285 · DOI · Paper page
- 10.1158/0008-5472.CAN-12-3767 · DOI
- 10.1158/0008-5472.CAN-06-2201 · DOI · Paper page
- 10.1038/ng.3333 · DOI · Paper page
- 10.1038/nm.3930 · DOI · Paper page
- 10.1126/scisignal.aam7550 · DOI
- 10.1073/pnas.1706011114 · DOI
- 10.1038/nm.3667 · DOI · Paper page
- 10.1038/nature11003 · DOI · Paper page
- 10.1073/pnas.93.9.4181 · DOI · Paper page
- 10.1038/sj.onc.1209840 · DOI
- 10.1016/j.cels.2017.05.009 · DOI · Paper page
- 10.1016/j.bbamcr.2011.03.010 · DOI · Paper page
- 10.1038/nrc3580 · DOI · Paper page
- 10.1007/s12032-013-0805-3 · DOI · Paper page
- 10.2337/db08-1388 · DOI · Paper page
- B. Desbuquois, N. Carré, A. F. Burnol, Regulation of insulin and type 1 insulin-like growth factor signaling and action by the Grb10/14 and SH2B1/B2 adaptor proteins. FEBS J. 280, 794–816 (2013). · DOI · Paper page
- 10.1042/bj3350103 · DOI
- 10.4161/cc.10.11.15824 · DOI · Paper page
- 10.1085/jgp.8.6.519 · DOI · Paper page
- 10.1074/jbc.M114.564070 · DOI
- 10.1007/s10495-009-0331-0 · DOI
- 10.1038/onc.2016.410 · DOI
- 10.1111/j.1600-0854.2011.01178.x · DOI · Paper page
- 10.1038/nm.1890 · DOI · Paper page
- 10.1038/onc.2017.288 · DOI
- 10.1158/0008-5472.CAN-06-0792 · DOI · Paper page
- 10.1158/0008-5472.CAN-09-2598 · DOI
- 10.1158/1535-7163.MCT-17-0413 · DOI
- 10.1007/978-1-4939-3049-4_17 · DOI
- 10.1021/acs.jproteome.7b00602 · DOI · Paper page
- 10.1021/pr500893m · DOI · Paper page
- 10.1021/pr500985w · DOI · Paper page
- 10.1038/nbt.1511 · DOI · Paper page
- 10.1021/pr101065j · DOI · Paper page
- 10.1074/mcp.M113.031591 · DOI · Paper page
- 10.1038/nprot.2008.211 · DOI · Paper page
- 10.1093/nar/gku1003 · DOI · Paper page
- 10.1038/nmeth1109-786 · DOI · Paper page
- 10.1093/bioinformatics/19.2.185 · DOI · Paper page
- 10.1038/sj.onc.1200849 · DOI · Paper page
- 10.1158/1078-0432.CCR-14-2024 · DOI
- 10.1074/jbc.M501972200 · DOI · Paper page
Cited by
INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases
Beekhof, R., van Alphen, C., Henneman, A. A., Knol, J. C., Pham, T. V., Rolfs, F., Labots, M., Henneberry, E., Le Large, T. Y., de Haas, R. R., et al. (2019) · Molecular Systems Biology · doi:10.15252/msb.20188250 · Cited by 97
Wu, Q., Tian, A.-L., Li, B., Leduc, M., Forveille, S., Hamley, P., Galloway, W., Xie, W., Liu, P., Zhao, L., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002722 · Cited by 83
Mari, T., Mösbauer, K., Wyler, E., Landthaler, M., Drosten, C., & Selbach, M. (2022) · Journal of Proteome Research · doi:10.1021/acs.jproteome.2c00198 · Cited by 70
Metadata
- Authors
- Emdal, K. B., Pedersen, A.-K., Bekker-Jensen, D. B., Lundby, A., Claeys, S., De Preter, K., Speleman, F., Francavilla, C., & Olsen, J. V.
- Venue
- Science Signaling
- Published
- 2018-11-20
- Volume
- 11
- Issue
- 557
- ISSN
- 1937-9145 (ISSN-L)
- 1945-0877
- OpenAlex
- W2900564926
- Cited by
- 42
- References
- 9
- FWCI
- 2.82
- Type
- journal article
- Language
- en
- Open access
- green
- Funders
- Lundbeckfonden (R191-2015-703)
- Novo Nordisk Foundation (NNF14CC0001)
- European Union’s Horizon 2020 research and innovation programme (686547)
- EMBO long-term fellowship (ALTF 746-2009)
- Danish Cancer Society (R90-A5844)
- Wellcome Trust Sir Henry Dale fellowship (8107636/Z/15/Z)
- European Union’s 7th Framework Programme (259348-ASSET)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.